Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANAMO: IFX-1 in patients with severe COVID-19 pneumonia
2020-001335-28Phase 2Completed
- Sponsor
- InflaRx
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial in coronavirus disease 2019 (COVID-19), pneumonia and viral pneumonia comparing IFX-1 with control (standard of care) (2 arms). Primary endpoint: Phase II primary endpoint. Started Mar 2020; status: completed.
02
Drugs
vilobelimab
03
Conditions
coronavirus disease 2019 (COVID-19)pneumoniaviral pneumonia
Beyond the preview
Go deeper on 2020-001335-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001335-28.